Pro golfer Aza Muñoz
featured on The Balancing Act®
airing on Lifetime TV®

Watch Aza on The Balancing Act Ways to Save

Aza Muñoz, professional golfer (sponsored by Tirosint-SOL),
has Hashimoto’s thyroiditis.

Living with hypothyroidism can be a challenging journey. For professional golfer Azahara Muñoz, the journey with Hashimoto’s thyroiditis began in 2016 when she started experiencing unexplained fatigue and hair loss. At first, she struggled to understand the condition and how to manage it. But with the help of her doctors and a supportive community, she has learned to live with the disease and manage her symptoms.

Aza was recently featured on The Balancing Act® morning show airing on Lifetime TV® with her endocrinologist, Dr. Kenilia Ventura. In this personal account, the segment explores Aza’s journey with the disease and the challenges she has faced along the way. The segment also highlights the importance of proper thyroid function and new approaches hypothyroid patients can take to make treatment more successful.

Read the Article

Watch Aza Muñoz on The Balancing Act®

Jump to one of the three topics covered in this video

Find out if Tirosint-SOL is right for you. Take this self-assessment and bring to your doctor.

Go to Self-Assessment
Go to Spanish Self-Assessment
Tirosint-SOL Logo

Tirosint-SOL Important Safety Information



IMPORTANT SAFETY INFORMATION for TIROSINT-SOL (levothyroxine sodium) ORAL SOLUTION

WARNING: NOT FOR THE TREATMENT OF OBESITY OR FOR WEIGHT LOSS

Thyroid hormones, including TIROSINT-SOL, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss.

In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.

Contraindications 

  • Hypersensitivity to glycerol
  • Uncorrected adrenal insufficiency

Warnings and Precautions 

  • Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease: Initiate TIROSINT-SOL at less than the full replacement dose because of the increased risk of cardiac adverse reactions, including atrial fibrillation
  • Myxedema coma: Do not use oral thyroid hormone drug products to treat myxedema coma
  • Acute adrenal crisis in patients with concomitant adrenal insufficiency: Treat with replacement glucocorticoids prior to initiation of TIROSINT-SOL treatment
  • Prevention of hyperthyroidism or incomplete treatment of hypothyroidism: Proper dose titration and careful monitoring is critical to prevent the persistence of hypothyroidism or the development of hyperthyroidism
  • Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing thyroid hormone therapy
  • Decreased bone mineral density associated with thyroid hormone over-replacement: Over-replacement can increase bone reabsorption and decrease bone mineral density. Give the lowest effective dose

Limitations of Use 

  • Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients
  • Not indicated for treatment of transient hypothyroidism during the recovery phase of subacute thyroiditis

Adverse Reactions

Adverse reactions associated with TIROSINT-SOL are primarily those of hyperthyroidism due to therapeutic overdosage including: arrhythmias, myocardial infarction, dyspnea, muscle spasm, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash

For more information, visit www.ibsagroup.com/media
*For Full Prescribing Information, visit www.TirosintSOL.com